Revolutionizing clinical trials: A discussion on diversity and patient-centric approaches

As medicines have become more complex, the cost of clinical trials has risen significantly, and newly imposed measurements and endpoints can prove challenging to patients. Low trial enrollment, lack of racial diversity, and exclusion of people with comorbidities create additional considerations for trial sponsors.

In our latest episode of At the Intersection of Science and Law, Quest Diagnostics’ Adam Donat joins DLA Piper Senior Policy Advisor Kirsten Axelsen (New York), Policy Advisor Rachel Portman (Atlanta), and Partner Jae Kim (Philadelphia) to discuss the growing complexities of clinical trials, key FDA guidance for sponsors, innovative trial designs and tools, and what is expected in the new year.

Listen to the At the Intersection of Science and Law podcast on iTunes and Spotify.